Table 1.
Baseline patient characteristics (n = 379).
| Characteristics | Value |
|---|---|
| Age (years) | |
| Median (IQR) | 65 (58–71) |
| ≥65 years, n (%) | 189 (49.9) |
| ≥70 years, n (%) | 108 (28.5) |
| Male, n (%) | 226 (59.6) |
| Caucasian, n (%) | 355 (93.7) |
| ECOG performance status, n (%) | |
| 0 | 117 (30.9) |
| 1 | 255 (67.3) |
| 2 | 7 (1.8) |
| Site of primary tumour, n (%) | |
| Colon | 222 (58.6) |
| Rectum | 129 (34.0) |
| Colon and rectum | 27 (7.1) |
| Unknown | 1 (0.3) |
| Primary tumour surgery, n (%) | 316 (83.4) |
| Timing of metastases from initial diagnosis, n (%) | |
| Synchronous (≤6 months) | 231 (60.9) |
| Metachronous (>6 months) | 148 (39.1) |
| Site of metastasis (frequency ≥10%), n (%) a | |
| Liver | 262 (69.1) |
| Lung | 256 (67.5) |
| Peritoneum | 93 (24.5) |
| Distant node | 70 (18.5) |
| Bone | 29 (7.7) |
| Number of metastatic sites, n (%) | |
| ≤2 | 279 (73.6) |
| ≥3 | 100 (26.4) |
| Lines of treatment, n (%) | |
| <3 | 126 (33.2) |
| ≥3 | 253 (66.8) |
| Previous therapies in ≥1 line, n (%) a | |
| Fluoropyrimidines | 379 (100) |
| Oxaliplatin | 333 (87.9) |
| Irinotecan | 378 (99.7) |
| Anti-VEGF | 339 (89.4) |
| Anti-EGFR | 117 (46.7) |
| Regorafenib | 60 (15.8) |
| Other | 83 (21.9) |
| Time from the initial diagnosis to start trifluridine/tipiracil (years), median (IQR) | 3.3 (2.2–5.3) |
| Time from metastasis diagnosis to start trifluridine/tipiracil (years) | |
| Median (IQR) | 2.5 (1.7–4.2) |
| ≥18 months, n (%) | 320 (84.4) |
ECOG: Eastern Cooperative Oncology Group, EGFR: epidermal growth factor receptor, IQR: interquartile range, VEGF: vascular endothelial growth factor. a Multi-response variable.